There are currently 219 clinical trials in Springfield, Illinois looking for participants to engage in research studies. Trials are conducted at various facilities, including Southern Illinois University School of Medicine, Memorial Medical Center, Springfield Clinic and Central Illinois Hematology Oncology Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A 6-Month Extension Study of VMDN-003-2 to Assess Engensis in Participants With Painful Diabetic Peripheral Neuropathy
NCT04873232
Recruiting
To evaluate the durability of efficacy and long-term safety of intramuscular (IM) administration of Engensis or Placebo that was administered in the double-blind, randomized, VMDN-003-2 Placebo-controlled Phase 3 Study.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/03/2022
Locations: Foot & Ankle Center of Illinois, Springfield, Illinois
Conditions: Diabetic Peripheral Neuropathy
Register for Updates
Evaluate the Safety and Efficacy of ON101 Cream for the Treatment of Chronic Diabetic Foot Ulcers
NCT04962139
Recruiting
The primary efficacy endpoint for this study is the proportion of subjects with complete closure of Target Ulcer during the 20-week Treatment Phase, which is assessed by the blinded independent evaluator.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
07/15/2022
Locations: Oneness Investigational Site, Springfield, Illinois
Conditions: Chronic Diabetic Foot Ulcers
Register for Updates
Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy
NCT04857359
Recruiting
This study is designed to evaluate the safety and efficacy of dipraglurant in PD patients with dyskinesia (randomized 1:1 to receive active or placebo) for 12 weeks (1 week at 150 mg per day and 11 weeks at 300 mg per day). The primary efficacy assessment will be based on the Unified Dyskinesia Rating Scale (UDysRS). Patients who complete the 12-week blinded treatment period may have the option to roll into an open-label safety extension study for an additional 12-month treatment period.
Gender:
All
Ages:
Between 30 years and 85 years
Trial Updated:
05/18/2022
Locations: Southern Illinois University School of Medicine, Springfield, Illinois
Conditions: Parkinson Disease, Dyskinesia, Drug-Induced, Dyskinesias
Register for Updates